Testing for Inherited Thrombophilia in Recurrent Miscarriage

ABSTRACT

Approximately 1–5% of women trying to conceive experience recurrent miscarriage, and in 50% of these women, the cause of the preceding miscarriages is unknown. Inherited thrombophilias such as factor V Leiden mutation, prothrombin gene mutation (PT 20210A), and deficiencies of natural anticoagulants protein C, protein S, and antithrombin are associated with recurrent miscarriage. Knowledge of the association between inherited thrombophilia and recurrent miscarriage and of potential treatment options for improving chances of a live birth could tempt physicians to test for inherited thrombophilia in women with recurrent miscarriage. However, the strength of the association between inherited thrombophilia and recurrent miscarriage is not very strong, and more importantly, no evidence indicates that the use of anticoagulants improves the chance of live birth in these women. With the current state of evidence, testing for inherited thrombophilia should not lead to altered clinical management and therefore, should not be performed routinely in women with recurrent miscarriage but only in the context of scientific studies.

KEYWORDS

Pregnancy - inherited thrombophilia - adverse pregnancy outcome - recurrent miscarriage

REFERENCES

• 1 Farquharson R G, Jauniaux E, Exalto N. ESHRE Special Interest Group for Early Pregnancy (SIGEP) . Updated and revised nomenclature for description of early pregnancy events.  Hum Reprod. 2005;  20 (11) 3008-3011
• 2 Kaandorp S P, Goddijn M, van der Post J A et al.. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.  N Engl J Med. 2010;  362 (17) 1586-1596
• 3 van den Boogaard E, Kaandorp S P, Franssen M T et al.. Consecutive or non-consecutive recurrent miscarriage: is there any difference in carrier status?.  Hum Reprod. 2010;  25 (6) 1411-1414
• 4 Regan L, Rai R. Epidemiology and the medical causes of miscarriage.  Best Pract Res Clin Obstet Gynaecol. 2000;  14 (5) 839-854
• 5 Poland B J, Miller J R, Jones D C, Trimble B K. Reproductive counseling in patients who have had a spontaneous abortion.  Am J Obstet Gynecol. 1977;  127 (7) 685-691
• 6 Sierra S, Stephenson M. Genetics of recurrent pregnancy loss.  Semin Reprod Med. 2006;  24 (1) 17-24
• 7 Rai R, Regan L. Recurrent miscarriage.  Lancet. 2006;  368 (9535) 601-611
• 8 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis.  Lancet. 2003;  361 (9361) 901-908
• 9 Robertson L, Wu O, Langhorne P Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study et al. Thrombophilia in pregnancy: a systematic review.  Br J Haematol. 2006;  132 (2) 171-196
• 10 Morrison E R, Miedzybrodzka Z H, Campbell D M et al.. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review.  Thromb Haemost. 2002;  87 (5) 779-785
• 11 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.  JAMA. 1997;  277 (16) 1305-1307
• 12 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 (10) 3698-3703
• 13 Lockwood C J. Inherited thrombophilias in pregnant patients.  Prenat Neonatal Med. 2001;  6 3-14
• 14 Bank I, van de Poel M H, Coppens M et al.. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study.  Thromb Haemost. 2007;  98 (5) 1040-1044
• 15 Kamphuisen P W, Lensen R, Houwing-Duistermaat J J et al.. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia.  Br J Haematol. 2000;  109 (3) 519-522
• 16 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).  Blood. 1995;  85 (6) 1504-1508
• 17 Coppens M, Kaandorp S P, Middeldorp S. Inherited thrombophilias.  Obstet Gynecol Clin North Am. 2006;  33 (3) 357-374
• 18 Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients?.  Br J Haematol. 2008;  143 (3) 321-335
• 19 Cohn D M, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing.  Semin Thromb Hemost. 2007;  33 (6) 573-581
• 20 Hellgren M. Hemostasis during normal pregnancy and puerperium.  Semin Thromb Hemost. 2003;  29 (2) 125-130
• 21 Kujovich J L. Thrombophilia and pregnancy complications.  Am J Obstet Gynecol. 2004;  191 (2) 412-424
• 22 Salmon J E, Girardi G, Lockshin M D. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients.  Nat Clin Pract Rheumatol. 2007;  3 (3) 140-147; quiz 1, 187
• 23 Quenby S, Mountfield S, Cartwright J E, Whitley G S, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation.  Fertil Steril. 2005;  83 (3) 691-698
• 24 Bose P, Black S, Kadyrov M et al.. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.  Am J Obstet Gynecol. 2005;  192 (1) 23-30
• 25 Isermann B, Sood R, Pawlinski R et al.. The thrombomodulin-protein C system is essential for the maintenance of pregnancy.  Nat Med. 2003;  9 (3) 331-337
• 26 Ivanov P D, Komsa-Penkova R S, Konova E I, Kovacheva K S, Simeonova M N, Popov J D. Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss.  Blood Coagul Fibrinolysis. 2009;  20 (2) 134-140
• 27 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.  Eur J Obstet Gynecol Reprod Biol. 2002;  101 (1) 6-14
• 28 Hirsh J, Warkentin T E, Shaughnessy S G et al.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest. 2001;  119 (1, Suppl) 64S-94S
• 29 Badawy A M, Khiary M, Sherif L S, Hassan M, Ragab A, Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology.  J Obstet Gynaecol. 2008;  28 (3) 280-284
• 30 Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey A A, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study.  Arch Gynecol Obstet. 2008;  278 (1) 33-38
• 31 Clark P, Walker I D, Langhorne P Scottish Pregnancy Intervention Study (SPIN) collaborators et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.  Blood. 2010;  115 (21) 4162-4167
• 32 Laskin C A, Spitzer K A, Clark C A et al.. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.  J Rheumatol. 2009;  36 (2) 279-287
• 33 Visser J, Ulander V M, Helmerhorst F M et al.. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial.  Thromb Haemost. 2011;  105 (2) 295-301
• 34 Greer I A, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.  Blood. 2005;  106 (2) 401-407
• 35 Byrd L, Shiach C, Johnston T, Hay C. Osteopenic fractures in pregnancy: is low molecular weight heparin (LMWH) implicated?.  J Obstet Gynaecol. 2008;  28 (5) 539-542
• 36 Bank I, Libourel E J, Middeldorp S, Van Der Meer J, Büller H R. High rate of skin complications due to low-molecular-weight heparins in pregnant women.  J Thromb Haemost. 2003;  1 (4) 859-861
• 37 Machin S J. Pros and cons of thrombophilia testing: cons.  J Thromb Haemost. 2003;  1 (3) 412-413
• 38 Cohn D M, Vansenne F, Kaptein A A, De Borgie C A, Middeldorp S. The psychological impact of testing for thrombophilia: a systematic review.  J Thromb Haemost. 2008;  6 (7) 1099-1104
• 39 Hellmann E A, Leslie N D, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation.  J Thromb Haemost. 2003;  1 (11) 2335-2339
• 40 Lindqvist P G, Dahlbäck B. Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.  Acta Obstet Gynecol Scand. 2003;  82 (5) 467-470
• 41 Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.  Fertil Steril. 2006;  86 (2) 362-366